Design of a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of tezepelumab in adult patients with severe chronic rhinosinusitis with nasal polyposis (WAYPOINT)

Design of a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of tezepelumab in adult patients with severe chronic rhinosinusitis with nasal polyposis (WAYPOINT) Meeting Abstract

sustainable development goals

SDG 03: Good Health and Well-being

publication date

September 1, 2024

webpage

Web of Science

published in

ALLERGOLOGIE Journal

volume

47

issue

9